Inhalation compositions comprising muscarinic receptor antagonist

US 10,105,316 B2
Filed: 06/27/2013
Issued: 10/23/2018
Est. Priority Date: 07/05/2012
Status: Active Grant

First Claim

Patent Images

1. A dry powder inhalation composition comprising,(a) at least one muscarinic receptor antagonist or a pharmaceutically acceptable salt thereof;

(b) fine particle lactose in the amount of 1-20% by weight of said composition and having a (d50) particle size in the range of 4-10 μ

m; and

(c) coarse particle mannitol in the amount of 80-99% by weight of said composition and having a (d50) particle size in the range of 50-120 μ

m and a (d90) particle size of 120-300 μ

m.

View all claims

5 Assignments

Timeline View

Assignment View

0 Petitions

Accused Products

Abstract

The invention relates to pharmaceutical powder compositions administered by means of inhalers. More particularly, it relates to pharmaceutical powder compositions having the content uniformity and the desired stability used in inhaler devices.

46 Citations

47 Claims

1. A dry powder inhalation composition comprising,(a) at least one muscarinic receptor antagonist or a pharmaceutically acceptable salt thereof;
- (b) fine particle lactose in the amount of 1-20% by weight of said composition and having a (d50) particle size in the range of 4-10 μ
  
  m; and
  
  (c) coarse particle mannitol in the amount of 80-99% by weight of said composition and having a (d50) particle size in the range of 50-120 μ
  
  m and a (d90) particle size of 120-300 μ
  
  m.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 44, 45, 46, 47)
- - 2. The pharmaceutical composition according to claim 1, wherein the (d50) particle size of said fine particle lactose is 4-7 μ
    - m, a (d10) particle size of said fine particle lactose is 1-5 μ
      
      m, and/or a (d90) particle size of said fine particle lactose is 7-20 μ
      
      m.
  - 3. The pharmaceutical composition according to claim 1, further comprising coarse particle lactose with a (d50) particle size of 50-80 μ
    - m, coarse particle lactose with a (d10) particle size of 10-50 μ
      
      m, and/or coarse particle lactose with a (d90) particle size of 120-300 μ
      
      m.
  - 4. The pharmaceutical composition according to claim 1, further comprising fine particle mannitol with a (d50) particle size of 4-7 μ
    - m;
      
      fine particle mannitol with a (d10) particle size of 1-5 μ
      
      m; and
      
      /or fine particle mannitol with a (d90) particle size of 10-20 μ
      
      m.
  - 5. The pharmaceutical composition according to claim 1, wherein the amount of said lactose is in the range of 1-15%, by weight of the composition.
  - 6. The pharmaceutical composition according to claim 1, wherein the amount of said course particle mannitol is in the range of 85-99% by weight of the composition.
  - 7. The pharmaceutical composition claim 1, wherein said muscarinic receptor antagonist is selected from the group consisting of at least one or a mixture of tiotropium, glycopyronium, aclidinium, darotropium, oxitropium, and ipratropium.
  - 8. The pharmaceutical composition according to claim 1, wherein said composition further comprises one or more β
    - 2-adrenergic agonists.
  - 9. The pharmaceutical composition according to claim 8, wherein said one or more beta-2 adrenergic agonists are selected from at least one or a mixture of salmeterol, formoterol, arformoterol, salbutamol, indacaterol, terbutaline, metaproterenol, vilanterol, carmoterol, olodaterol, bambuterol, and clenbuterol.
  - 10. The pharmaceutical composition according to claim 1, further comprising one or more corticosteroids selected from at least one or a mixture of ciclesonide, budesonide, fluticasone, aldosterone, beclomethasone, betametazone, chloprednol, cortisone, cortivasol, deoxycortone, desonide, desoxymethasone, dexamethasone, difluocortolone, fluchloralin, flumetasone, flunisolide, fluocinolone, fluocinonide, flurocortisone, fluocortolone, flurometolone, flurandrenolone, halcinonide, hydrocortisone, icometasone, meprednisone, methylprednisolone, mometasone, paramethasone, prednisolone, prednisone, tixocortole, and/or triamcinolone.
  - 11. The pharmaceutical composition according to claim 10, wherein the one or more corticosteroids are selected from ciclesonide, budesonide, fluticasone, and mometasone.
  - 12. The pharmaceutical composition according to claim 1, further comprising (a) one or more corticosteroids, (b) one or more β
    - 2-adrenergic agonists;
      
      or (c) one or more corticosteroids and one or more β
      
      2-adrenergic agonists.
  - 13. The pharmaceutical composition according to claim 1, further comprising an excipient selected from at least one or a mixture of glucose, glucose anhydrous, trehalose, cellobiose, and sorbitol.
  - 14. The pharmaceutical composition according to claim 1, wherein said composition comprises one of the following therapeutically active combinations:
    - i. Aclidinium and tiotropiumii. Aclidinium and glycopyrroniumiii. Aclidinium and darotropyumiv. Aclidinium and oxitropiumv. Aclidinium and ipratropiumvi. Aclidinium and ciclesonidevii. Aclidinium and budesonidviii. Aclidinium and fluticasoneix. Aclidinium and mometazonx. Tiotropium and glycopyrroniumxi. Tiotropium and darotropyumxii. Tiotropium and oxitropiumxiii. Tiotropium and ipratropiumxiv. Tiotropium and ciclesonidexv. Tiotropium and budesonidxvi. Tiotropium and fluticasonexvii. Tiotropium and mometazonxviii. Glycopyrronium and tiotropiumxix. Glycopyrronium and glycopyrroniumxx. Glycopyrronium and darotropyumxxi. Glycopyrronium and oxitropiumxxii. Glycopyrronium and ipratropiumxxiii. Glycopyrronium and ciclesonidexxiv. Glycopyrronium and budesonidxxv. Glycopyrronium and fluticasonexxvi. Glycopyrronium and mometazonxxvii. Oxitropium and tiotropiumxxviii. Oxitropium and darotropyumxxix. Oxitropium and aclidiniumxxx. Oxitropium and ipratropiumxxxi. Oxitropium and ciclesonidexxxii. Oxitropium and budesonidxxxiii. Oxitropium and fluticasonexxxiv. Oxitropium and mometazonxxxv. Darotropyum and tiotropiumxxxvi. Darotropyum and aclidiniumxxxvii. Darotropyum and oxitropiumxxxviii. Darotropyum and ipratropiumxxxix. Darotropyum and ciclesonidexl. Darotropyum and budesonidxli. Darotropyum and fluticasonexlii. Darotropyum and mometazonxliii. Aclidinium and salmeterolxliv. Aclidinium and formoterolxlv. Aclidinium and arformoterolxlvi. Aclidinium and salbutamolxlvii. Aclidinium and indacaterolxlviii. Aclidinium and vilanterolxlix. Aclidinium and carmoteroll. Aclidinium and olodaterolli. Aclidinium and bambuterollii. Tiotropium and salmeterolliii. Tiotropium and formoterolliv. Tiotropium and arformoterollv. Tiotropium and salbutamollvi. Tiotropium and indacaterollvii. Tiotropium and vilanterollviii. Tiotropium and carmoterollix. Tiotropium and olodaterollx. Tiotropium and bambuterollxi. Glycopyrronium and salmeterollxii. Glycopyrronium and formoterollxiii. Glycopyrronium and arformoterollxiv. Glycopyrronium and salbutamollxv. Glycopyrronium and indacaterollxvi. Glycopyrronium and vilanterollxvii. Glycopyrronium and carmoterollxviii. Glycopyrronium and olodaterollxix. Glycopyrronium and bambuterollxx. Oxitropium and salmeterollxxi. Oxitropium and formoterollxxii. Oxitropium and arformoterollxxiii. Oxitropium and salbutamollxxiv. Oxitropium and indacaterollxxv. Oxitropium and vilanterollxxvi. Oxitropium and carmoterollxxvii. Oxitropium and olodaterollxxviii. Oxitropium and bambuterollxxix. Darotropium and salmeterollxxx. Darotropium and formoterollxxxi. Darotropium and arformoterollxxxii. Darotropium and salbutamollxxxiii. Darotropium and indacaterollxxxiv. Darotropium and vilanterollxxxv. Darotropium and carmoterollxxxvi. Darotropium and olodaterollxxxvii. Darotropium and bambuterollxxxviii. Aclidinium, tiotropium and salmeterollxxxix. Aclidinium, tiotropium and formoterolxc. Aclidinium, tiotropium and arformoterolxci. Aclidinium, tiotropium and indacaterolxcii. Aclidinium, tiotropium and olodaterolxciii. Aclidinium, tiotropium and vilanterolxciv. Aclidinium, tiotropium and carmoterolxcv. Aclidinium, tiotropium and bambuterolxcvi. Aclidinium, glycopyrronium and salmeterolxcvii. Aclidinium, glycopyrronium and formoterolxcviii. Aclidinium, glycopyrronium and arformoterolxcix. Aclidinium, glycopyrronium and indacaterolc. Aclidinium, glycopyrronium and olodaterolci. Aclidinium, glycopyrronium and vilanterolcii. Aclidinium, glycopyrronium and carmoterolciii. Aclidinium, glycopyrronium and bambuterolciv. Aclidinium, oxitropium and salmeterolcv. Aclidinium, oxitropium and formoterolcvi. Aclidinium, oxitropium and arformoterolcvii. Aclidinium, oxitropium and indacaterolcviii. Aclidinium, oxitropium and olodaterolcix. Aclidinium, oxitropium and vilanterolcx. Aclidinium, oxitropium and carmoterolcxi. Aclidinium, oxitropium and bambuterolcxii. Glycopyrronium, tiotropium and salmeterolcxiii. Glycopyrronium, tiotropium and formoterolcxiv. Glycopyrronium, tiotropium and arformoterolcxv. Glycopyrronium, tiotropium and indacaterolcxvi. Glycopyrronium, tiotropium and olodaterolcxvii. Glycopyrronium, tiotropium and vilanterolcxviii. Glycopyrronium, tiotropium and carmoterolcxix. Glycopyrronium, tiotropium and bambuterolcxx. Glycopyrronium, oxitropium and salmeterolcxxi. Glycopyrronium, oxitropium and formoterolcxxii. Glycopyrronium, oxitropium and arformoterolcxxiii. Glycopyrronium, oxitropium and indacaterolcxxiv. Glycopyrronium, oxitropium and olodaterolcxxv. Glycopyrronium, oxitropium and vilanterolcxxvi. Glycopyrronium, oxitropium and carmoterolcxxvii. Glycopyrronium, oxitropium and bambuterolcxxviii. Daratropium, tiotropium and salmeterolcxxix. Daratropium, tiotropium and formoterolcxxx. Daratropium, tiotropium and arformoterolcxxxi. Daratropium, tiotropium and indacaterolcxxxii. Daratropium, tiotropium and olodaterolcxxxiii. Daratropium, tiotropium and vilanterolcxxxiv. Daratropium, tiotropium and carmoterolcxxxv. Daratropium, tiotropium and bambuterolcxxxvi. Daratropium, glycopyrronium and salmeterolcxxxvii. Daratropium, gikopironyum and formoterolcxxxviii. Daratropium, glycopyrronium and arformoterolcxxxix. Daratropium, glycopyrronium and indacaterolcxl. Daratropium, glycopyrronium and olodaterolcxli. Daratropium, glycopyrronium and vilanterolcxlii. Daratropium, glycopyrronium and carmoterolcxliii. Daratropium, glycopyrronium and bambuterolcxliv. Daratropium, aclidinium and salmeterolcxlv. Daratropium, aclidinium and formoterolcxlvi. Daratropium, aclidinium and arformoterolcxlvii. Daratropium, aclidinium and indacaterolcxlviii. Daratropium, aclidinium and olodaterolcxlix. Daratropium, aclidinium and vilanterolcl. Daratropium, aclidinium and carmoterolcli. Daratropium, aclidinium and bambuterolclii. Daratropium, oxitropium and salmeterolcliii. Daratropium, oxitropium and formoterolcliv. Daratropium, oxitropium and arformoterolclv. Daratropium, oxitropium and indacaterolclvi. Daratropium, oxitropium and olodaterolclvii. Daratropium, oxitropium and vilanterolclviii. Daratropium, oxitropium and carmoterolclix. Daratropium, oxitropium and bambuterolclx. İ
      
      ndacaterol, tiotropium and salmeterolclxi. İ
      
      ndacaterol, tiotropium and formoterolclxii. İ
      
      ndacaterol, tiotropium and arformoterolclxiii. İ
      
      ndacaterol, tiotropium and olodaterolclxiv. İ
      
      ndacaterol, tiotropium and vilanterolclxv. İ
      
      ndacaterol, tiotropium and carmoterolclxvi. İ
      
      ndacaterol, tiotropium and bambuterolclxvii. İ
      
      ndacaterol, glycopyrronium and salmeterolclxviii. İ
      
      ndacaterol, glycopyrronium and formoterolclxix. İ
      
      ndacaterol, glycopyrronium and arformoterolclxx. İ
      
      ndacaterol, glycopyrronium and olodaterolclxxi. İ
      
      ndacaterol, glycopyrronium and vilanterolclxxii. İ
      
      ndacaterol, glycopyrronium and carmoterolclxxiii. İ
      
      ndacaterol, glycopyrronium and bambuterolclxxiv. İ
      
      ndacaterol, aclidinium and salmeterolclxxv. İ
      
      ndacaterol, aclidinium and formoterolclxxvi. İ
      
      ndacaterol, aclidinium and arformoterolclxxvii. İ
      
      ndacaterol, aclidinium and olodaterolclxxviii. İ
      
      ndacaterol, aclidinium and vilanterolclxxix. İ
      
      ndacaterol, aclidinium and carmoterolclxxx. İ
      
      ndacaterol, aclidinium and bambuterolclxxxi. İ
      
      ndacaterol, oxitropium and salmeterolclxxxii. İ
      
      ndacaterol, oxitropium and formoterolclxxxiii. İ
      
      ndacaterol, oxitropium and arformoterolclxxxiv. İ
      
      ndacaterol, oxitropium and olodaterolclxxxv. İ
      
      ndacaterol, oxitropium and vilanterolclxxxvi. İ
      
      ndacaterol, oxitropium and carmoterolclxxxvii. İ
      
      ndacaterol, oxitropium and bambuterolclxxxviii. Vilanterol, tiotropium and salmeterolclxxxix. Vilanterol, tiotropium and formoterolcxc. Vilanterol, tiotropium and arformoterolcxci. Vilanterol, tiotropium and indacaterolcxcii. Vilanterol, tiotropium and olodaterolcxciii. Vilanterol, tiotropium and carmoterolcxciv. Vilanterol, tiotropium and bambuterolcxcv. Vilanterol, glycopyrronium and salmeterolcxcvi. Vilanterol, glycopyrronium and formoterolcxcvii. Vilanterol, glycopyrronium and arformoterolcxcviii. Vilanterol, glycopyrronium and indacaterolcxcix. Vilanterol, glycopyrronium and olodaterolcc. Vilanterol, glycopyrronium and carmoterolcci. Vilanterol, glycopyrronium and bambuterolccii. Vilanterol, aclidinium and salmeterolcciii. Vilanterol, aclidinium and formoterolcciv. Vilanterol, aclidinium and arformoterolccv. Vilanterol, aclidinium and indacaterolccvi. Vilanterol, aclidinium and olodaterolccvii. Vilanterol, aclidinium and carmoterolccviii. Vilanterol, aclidinium and bambuterolccix. Vilanterol, oxitropium and salmeterolccx. Vilanterol, oxitropium and formoterolccxi. Vilanterol, oxitropium and arformoterolccxii. Vilanterol, oxitropium and indacaterolccxiii. Vilanterol, oxitropium and olodaterolccxiv. Vilanterol, oxitropium and carmoterolccxv. Vilanterol, oxitropium and bambuterolccxvi. Carmoterol, tiotropium and salmeterolccxvii. Carmoterol, tiotropium and formoterolccxviii. Carmoterol, tiotropium and arformoterolccxix. Carmoterol, tiotropium and indacaterolccxx. Carmoterol, tiotropium and olodaterolccxxi. Carmoterol, tiotropium and vilanterolccxxii. Carmoterol, tiotropium and bambuterolccxxiii. Carmoterol, glycopyrronium and salmeterolccxxiv. Carmoterol, glycopyrronium and formoterolccxxv. Carmoterol, glycopyrronium and arformoterolccxxvi. Carmoterol, glycopyrronium and indacaterolccxxvii. Carmoterol, glycopyrronium and olodaterolccxxviii. Carmoterol, glycopyrronium and vilanterolccxxix. Carmoterol, glycopyrronium and bambuterolccxxx. Carmoterol, aclidinium and salmeterolccxxxi. Carmoterol, aclidinium and formoterolccxxxii. Carmoterol, aclidinium and arformoterolccxxxiii. Carmoterol, aclidinium and indacaterolccxxxiv. Carmoterol, aclidinium and olodaterolccxxxv. Carmoterol, aclidinium and vilanterolccxxxvi. Carmoterol, aclidinium and bambuterolccxxxvii. Carmoterol, oxitropium and salmeterolccxxxviii. Carmoterol, oxitropium and formoterolccxxxix. Carmoterol, oxitropium and arformoterolccxl. Carmoterol, oxitropium and indacaterolccxli. Carmoterol, oxitropium and olodaterolccxlii. Carmoterol, oxitropium and vilanterolccxliii. Carmoterol, oxitropium and bambuterolccxliv. Olodaterol, tiotropium and salmeterolccxlv. Olodaterol, tiotropium and formoterolccxlvi. Olodaterol, tiotropium and arformoterolccxlvii. Olodaterol, tiotropium and indacaterolccxlviii. Olodaterol, tiotropium and vilanterolccxlix. Olodaterol, tiotropium and bambuterolccl. Olodaterol, glycopyrronium and salmeterolccli. Olodaterol, glycopyrronium and formoterolcclii. Olodaterol, glycopyrronium and arformoterolccliii. Olodaterol, glycopyrronium and indacaterolccliv. Olodaterol, glycopyrronium and vilanterolcclv. Olodaterol, glycopyrronium and bambuterolcclvi. Olodaterol, aclidinium and salmeterolcclvii. Olodaterol, aclidinium and formoterolcclviii. Olodaterol, aclidinium and arformoterolcclix. Olodaterol, aclidinium and indacaterolcclx. Olodaterol, aclidinium and vilanterolcclxi. Olodaterol, aclidinium and bambuterolcclxii. Olodaterol, oxitropium and salmeterolcclxiii. Olodaterol, oxitropium and formoterolcclxiv. Olodaterol, oxitropium and arformoterolcclxv. Olodaterol, oxitropium and indacaterolcclxvi. Olodaterol, oxitropium and vilanterolcclxvii. Olodaterol, oxitropium and bambuterolwherein each of the above therapeutic agents can be present as a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture.
  - 15. The pharmaceutical composition according to claim 1, wherein said composition comprises a blister having air and moisture barrier property, enabling simultaneous, respective and synchronic application.
  - 16. The pharmaceutical composition according to claim 1, wherein said composition comprises a blister having air and moisture tightness property, enabling simultaneous, respective and synchronic application.
  - 17. The pharmaceutical composition according to claim 1, wherein said composition comprises a dry powder inhaler device suitable for simultaneous, respective and synchronic application in a blister and having at least one locking mechanism ensuring the device to be maintained locked in both of the positions in which it is ready for inhalation and its lid is closed and ensuring the device to be automatically re-set once the lid is closed.
  - 18. The pharmaceutical composition according to claim 1, wherein said composition comprises a dry powder inhaler device suitable for simultaneous, respective and synchronic application in a capsule.
  - 19. The pharmaceutical composition according to claim 1, wherein the amount of said fine particle lactose is in the range of 1-10% by weight of said composition.
  - 20. The pharmaceutical composition according to claim 1, wherein the amount of said course particle mannitol is in the range of 90-99% by weight of the composition.
  - 21. The pharmaceutical composition according to claim 1, wherein said coarse particle mannitol has a (d10) particle size of 10-50 μ
    - m.
  - 22. The pharmaceutical composition according to claim 21, wherein said fine particle lactose has a (d10) particle size of 1-4 μ
    - m.
  - 23. The pharmaceutical composition according to claim 21, wherein said fine particle lactose has a (d90) particle size of 7-15 μ
    - m.
  - 24. The pharmaceutical composition according to claim 21, wherein said fine particle lactose has a (d10) particle size of 1-4 μ
    - m and a (d90) particle size of 7-15 μ
      
      m.
  - 25. The pharmaceutical composition according to claim 1, further comprising coarse particle lactose with a (d50) particle size of 50-120 μ
    - m.
  - 26. The pharmaceutical composition according to claim 1, further comprising coarse particle lactose with a (d50) particle size of 50-120 μ
    - m and a (d10) particle size of 10-50 μ
      
      m.
  - 27. The pharmaceutical composition according to claim 1, further comprising coarse particle lactose with a (d50) particle size of 50-120 μ
    - m and a (d90) particle size of 120-300 μ
      
      m.
  - 28. The pharmaceutical composition according to claim 1, further comprising fine particle mannitol with a (d50) particle size of 4-10 μ
    - m.
  - 29. The pharmaceutical composition according to claim 1, further comprising fine particle mannitol with a (d50) particle size of 4-10 μ
    - m and a (d10) particle size of 1-5 μ
      
      m.
  - 30. The pharmaceutical composition according to claim 1, further comprising fine particle mannitol with a (d50) particle size of 4-10 μ
    - m and a (d90) particle size of 7-20 μ
      
      m.
  - 31. The pharmaceutical composition according to claim 1, wherein the coarse particle mannitol has a (d50) particle size of 50-75 μ
    - m.
  - 32. The pharmaceutical composition according to claim 1, wherein the coarse particle mannitol has a (d90) particle size of 75-250 μ
    - m.
  - 33. The pharmaceutical composition according to claim 1, wherein a ratio of the (d50) particle size to the (d90) particle size equals to 0.40 or greater for the coarse particle mannitol.
  - 34. The pharmaceutical composition according to claim 33, wherein the mannitol is spray-dried mannitol.
  - 35. The pharmaceutical composition according to claim 1, wherein a ratio of the (d50) particle size to the (d90) particle size is between 0.45 and 0.50 for the coarse particle mannitol.
  - 36. The pharmaceutical composition according to claim 1, wherein a ratio of the (d50) particle size to the (d90) particle size is between 0.50 and 0.70 for the coarse particle mannitol.
  - 44. A method of treating chronic obstructive pulmonary disease in a mammalian subject, comprising administering to the subject a pharmaceutical composition according to claim 1.
  - 45. The method according to claim 44, wherein a pharmaceutically acceptable amount of said composition is administered once a day or twice a day.
  - 46. A method of treating asthma in a mammalian subject, comprising administering to the subject a pharmaceutical composition according to claim 1.
  - 47. The method according to claim 46, wherein a pharmaceutically acceptable amount of said composition is administered once a day or twice a day.

37. A dry powder inhalation composition comprising,at least one muscarinic receptor antagonist or a pharmaceutically acceptable salt thereof, fine particle lactose in the amount of 1-20% by weight of said composition and having a (d50) particle size in the range of 4-10 μ
- m and coarse particle mannitol in the amount of 80-99% by weight of said composition and having a (d50) particle size in the range of 50-120 μ
  
  m, wherein said fine particle lactose has a (d10) particle size of 1-5 μ
  
  m.

38. A dry powder inhalation composition comprising,at least one muscarinic receptor antagonist or a pharmaceutically acceptable salt thereof, fine particle lactose in the amount of 1-20% by weight of said composition and having a (d50) particle size in the range of 4-10 μ
- m and coarse particle mannitol in the amount of 80-99% by weight of said composition and having a (d50) particle size in the range of 50-120 μ
  
  m, wherein said fine particle lactose has a (d90) particle size of 7-20 μ
  
  m.

39. A dry powder inhalation composition comprising,(a) at least one muscarinic receptor antagonist or a pharmaceutically acceptable salt thereof;
- (b) fine particle lactose in the amount of 1-20% by weight of said composition and having a (d50) particle size in the range of 4-10 μ
  
  m; and
  
  (c) coarse particle mannitol in the amount of 80-99% by weight of said composition and having a (d50) particle size in the range of 50-120 μ
  
  m and a (d10) particle size of 10-50 μ
  
  m.
- View Dependent Claims (40, 41, 42, 43)
- - 40. The pharmaceutical composition according to claim 39, wherein the fine particle lactose has a (d50) particle size of 4-7 μ
    - m.
  - 41. The pharmaceutical composition according to claim 39, wherein the fine particle lactose has a (d50) particle size of 4-7 μ
    - m and a d(10) particle size of 1-4 μ
      
      m.
  - 42. The pharmaceutical composition according to claim 39, wherein the fine particle lactose has a (d50) particle size of 4-7 μ
    - m and a d(90) particle size of 7-15 μ
      
      m.
  - 43. The pharmaceutical composition according to claim 39, wherein the fine particle lactose has a (d50) particle size of 4-7 μ
    - m, a d(10) particle size of 1-4 μ
      
      m, and a d(90) particle size of 7-15 μ
      
      m.

Specification

Resources

Litigation Campaign Assessment

Current Assignee
Arven Ilac San. ve Tic. A.S.
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret A S
Inventors
Cifter, Umit, Turkyilmaz, Ali, Mutlu, Onur
Primary Examiner(s)
Palenik, Jeffrey T.

Application Number

US14/412,595
Publication Number

US 20150157567A1
Time in Patent Office

1,944 Days
Field of Search

None
US Class Current
CPC Class Codes

A61K 2300/00   Mixtures or combinations of...

A61K 31/137   Arylalkylamines, e.g. amphe...

A61K 31/138   Aryloxyalkylamines, e.g. pr...

A61K 31/167   having the nitrogen of a ca...

A61K 31/24   having an amino or nitro group

A61K 31/27   of carbamic or thiocarbamic...

A61K 31/40   having five-membered rings ...

A61K 31/439   the ring forming part of a ...

A61K 31/44   Non condensed pyridines; Hy...

A61K 31/46   8-Azabicyclo [3.2.1] octane...

A61K 31/4704   2-Quinolinones, e.g. carbos...

A61K 31/538   ortho- or peri-condensed wi...

A61K 31/569   substituted in position 17 ...

A61K 31/573   substituted in position 21,...

A61K 31/58   containing heterocyclic rin...

A61K 45/06   Mixtures of active ingredie...

A61K 9/0075   for inhalation via a dry po...

A61K 9/1623   Sugars or sugar alcohols, e...

A61M 15/0025   with caps

A61M 15/003   using capsules, e.g. to be ...

A61M 15/0045 : using multiple prepacked do...

A61M 2202/064 : Powder

A61M 2205/19 : Constructional features of ...

View All

Inhalation compositions comprising muscarinic receptor antagonist

First Claim

5 Assignments

0 Petitions

Accused Products

Abstract

46 Citations

47 Claims

Specification

Solutions

Use Cases

Quick Links

Inhalation compositions comprising muscarinic receptor antagonist

First Claim

5 Assignments

Subscription Required

Subscription Required

0 Petitions

Subscription Required

Accused Products

Subscription Required

Abstract

46 Citations

47 Claims

Specification

Subscription Required

Solutions

Use Cases

Quick Links